Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Risankizumab
Monoclonal Antibody · Immunosuppressant
Monoclonal AntibodyImmunosuppressant
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Manufacturer advises avoid (limited information available)
FDA category + note
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- BaricitinibSevereDatabaseDDInter
- CertolizumabSevereDatabaseDDInter
- CladribineSevereDatabaseDDInter
Mechanism
Risankizumab is a humanized monoclonal antibody that selectively targets and binds to the p19 subunit of the IL-23 receptor complex. This binding blocks the activity of interleukin-23 and subsequently inhibits the IL-23-dependent proinflammatory effect.
Indications
Moderate-to-severe plaque psoriasisActive psoriatic arthritis
Dosing
- Adult
- 150 mg administered subcutaneously at weeks 0 and 4, and every 12 weeks thereafter. Consider discontinuation if no response after 16 weeks.
Pharmacokinetics
Peak effect
3–14 days after SC dosing
Half-life
28 days
Bioavailability
89%
Contraindications
- Clinically significant active infection
Side effects
Common
AstheniaHeadachesIncreased risk of infectionPruritusFatigueArthralgiaNasopharyngitisSkin rashesLocal injection reactions
Serious
- Severe infections
- Reactivation of tuberculosis
- Skin cancer
- may increase risk of infections
Pregnancy & lactation
Pregnancy
Manufacturer advises avoid (limited information available)
Lactation
Manufacturer advises avoid (no information in)
Drug interactions
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Etanercept
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Fingolimod
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Golimumab
Severe
Database
Clinical effect not specified
Source: DDInter
Infliximab
Severe
Database
Clinical effect not specified
Source: DDInter
Leflunomide
Severe
Database
Clinical effect not specified
Source: DDInter
Measles Virus Vaccine Live Attenuated
Severe
Database
Clinical effect not specified
Source: DDInter
Mumps Virus Strain B Level Jeryl Lynn Live Antigen
Severe
Database
Clinical effect not specified
Source: DDInter
Natalizumab
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other Monoclonal Antibody drugs
Ask House about Risankizumab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team